Advertisement
Journal Home
Search for

Volume 187, Issue 1, Pages 33-38 (January 2004)


View previous. 9 of 41 View next.

Incidence and treatment of recurrent plantar fibromatosis by surgery and postoperative radiotherapy

Eelco de Bree, M.D.a, Frans A.N Zoetmulder, M.D., Ph.D.aCorresponding Author Informationemail address, Ronald B Keus, M.D.b, Hans L Peterse, M.D.c, Frits van Coevorden, M.D, Ph.D.a

Received 29 April 2002; received in revised form 16 November 2002

Abstract 

Background

The incidence of plantar fibromatosis (PF) is unknown. Sometimes PF tends to recur repetitively after surgical treatment. In our institute we have used postoperative radiotherapy in an attempt to diminish the change on recurrence.

Methods

The Dutch Network and National Database for Pathology (PALGA) was consulted to establish the incidence of plantar fibromatosis (PF). Data from 9 patients (11 feet) with PF referred to our institute for recurrent disease were analyzed and the role of postoperative radiotherapy in prevention of recurrence was studied.

Results

An average of 1.2 operations for PF was performed per 100,000 citizens yearly in the Netherlands. Twenty-six operations were performed and postoperative radiotherapy was used in 6 cases. Plantar fasciectomy was associated with the lowest recurrence rate. After microscopically incomplete excision or excision of early recurrence (≤6 months) alone all tumors recurred, while recurrence was rarely observed after adjuvant radiotherapy. However, radiotherapy was associated with significantly impaired functional outcome in 3 cases.

Conclusions

Plantar fibromatosis is relatively rare. Plantar fasciectomy seems to be the operation of choice. Although effective in decreasing the recurrence rate, adjuvant radiotherapy should be used very selectively because of its serious side effects.

a Department of Surgical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands

b Department of Radiotherapy, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam, Netherlands

c Department of Pathology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam, Netherlands

Corresponding Author InformationCorresponding author. Tel.: +0031-20-5122550; fax: +0031-20-5122554.

PII: S0002-9610(03)00432-X

doi:10.1016/j.amjsurg.2002.11.002


View previous. 9 of 41 View next.

Advertisement